Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well FR901228 works in treating patients with recurrent
small cell lung cancer. FR901228 may stop the growth of tumor cells by blocking the enzymes
necessary for their growth.